Executive Member Biography
Professor Bryan Burmeister
MB ChB, FF Rad (T), FRANZCR, MD
ANZMTG Executive Chairman
Professor Bryan Burmeister is currently the Director of Radiation Oncology at Princess Alexandra Hospital in Brisbane, Australia. Since 1997 he has been on the staff of the Faculty of Health Sciences, University of Queensland where he is involved in teaching medical students. He is frequently invited to speak at both national and international meetings and has a major interest in clinical trials involving melanoma and oesophageal cancer. His research achievements in the last six years include being a principal or co-investigator on over 20 clinical trials/projects, a number of which have been awarded funding by the Australian National Health and Medical Research Council. He has over 25 proffered papers at learned society meetings and has published over 70 papers in major journals. He has recently completed his degree of Doctor of Medicine at the University of Queensland. He also has a strong involvement in serving the professional community. He is currently the President of the Trans Tasman Radiation Oncology Group and is deputy chair of the Medical and Scientific Advisory Committee of Queensland Cancer Council. He has sat on a number of grant review panels and is a frequent manuscript reviewer for prestigious oncology journals.
Doctor Anne Cust
BA, BSc, MPH, PhD
ANZMTG Executive Member
Doctor Anne Cust is a Senior Research Fellow and Cancer Epidemiologist based at the Cancer Epidemiology and Services Research Group, Sydney School of Public Health, The University of Sydney. She is the recipient of an NHMRC Career Development Award (2014-2018), and an Early Career Development Fellowship from the Cancer Institute NSW (2011-2015). Her qualifications include BSc and BA degrees from The University of Queensland, and a PhD and MPH (Honours) degrees from the University of Sydney. In 2007, she was awarded the NSW Cancer Institute Premier's Award for Outstanding Research Scholar, which is given “in recognition of the potential to develop a highly significant career in cancer research”. Her main research interest is melanoma. She conducts collaborative research aimed primarily at identifying genetic and environmental causes of melanoma, and improving outcomes for people with melanoma. She is an Investigator on the Australian Melanoma Family Study, and plays a key role in international melanoma consortia, including as a member of the Analysis Team of the international Genetics of Melanoma (GenoMEL) Consortium, a Steering Member of the InterMEL consortium, and a member of the Genes, Environment and Melanoma (GEM) consortium.
 Associate Professor Gerald Fogarty
BSc, MBBS, FRANZCR, PhD
ANZMTG Executive Member
Associate Professor Gerald Fogarty is a Senior Consultant Radiation Oncologist. His subspecialty interests are Skin, and Genitourinary cancers. He is the Director of Radiation Oncology at the Mater Hospital, Sydney and has appointments at St Vincent’s Public and Private Hospitals Sydney, Skin and Cancer Foundation and Macquarie University Hospitals. He is also part of the Clinical Services group of Melanoma Institute Australia. He completed his specialist training at the Peter MacCallum Cancer Centre, Melbourne which included a laboratory based fellowship in translational research. His PhD is entitled “Advances in the Radiotherapy of Skin Cancers”. He has spearheaded the use of Intensity Modulated Radiotherapy, Volumetric Modulated Arc Therapy and stereotactic therapies, all modern radiotherapy techniques, at St Vincent’s and the Mater Hospitals. He has over 50 publications and presented at national and international conferences. He has NHMRC funding to over $1 million as the Principal Investigator of an ANZMTG led international randomised controlled trial to investigate radiotherapy in melanoma. From 2012, he has also been the Master of Warrane College, a residential College on campus of the University of NSW.
Doctor Victoria Mar
MBBS, FACD, PhD
ANZMTG Executive Member
Doctor Victoria Mar is a dermatologist specialising in melanoma based at Armadale Dermatology and The Alfred Hospital in Melbourne, Victoria. She is a Fellow of the Australian College of Dermatologists. She trained in Melbourne at the Alfred, Austin and Royal Melbourne Hospitals and at St George's Hospital, London. In addition to her private practice, she has an appointment at the Victorian Melanoma Service, Alfred Hospital and Royal Women's Hospital. She is currently undertaking a PhD at the Alfred Hospital and Peter McCallum Cancer Institute, investigating the clinical and molecular characteristics of nodular melanoma as part of the Melbourne Melanoma Project (MMP). She has published on melanoma risk and has a keen interest in early detection and prevention. Her experience in translational research projects involves exome sequencing of melanomas, with local and interstate collaborators in the areas of pathology, molecular pathology and bioinformatics. Her other areas of expertise include epidemiological studies and survival analyses with assistance from the Victorian Cancer Registry.
 Mr Richard Martin
MBChB, FRACS, ChM
ANZMTG Executive Member
Mr Richard Martin is a New Zealand trained General Surgeon who spent two and a half years at the Sydney Cancer Center specialising in Melanoma and Head/Neck surgery. Most of his time was spent at the Sydney Melanoma Unit, the largest treatment and research facility for melanoma in the world. During his time in Sydney, he completed a Master of Surgery in Surgical Oncology at the University of Sydney. Richard currently works in the multidisciplinary New Zealand Melanoma Unit team, Waitemata District Health Board (Northshore and Waitakere), and is part of the Auckland Regional Head and Neck Service. He is also a Senior Lecturer at the University of Auckland. Richard has published in numerous academic journals, is a regular presenter at international conferences and is actively involved in research and clinical trials. Richard is the chairman of the New Zealand Melanoma Standards Group, a board member of both the Melanoma Foundation of New Zealand and the Melanoma Network of New Zealand (MELNET). Richard is married to Geraldine and father to twin girls, he is also an avid Formula One fan!
Doctor Donna Milne
BNurs, Dip CanNurs/Pall, MNurs, PhD
ANZMTG Executive Member
Doctor Donna Milne is an Advanced Practice Nurse/Nurse Coordinator in the Skin and Melanoma Service at the Peter MacCallum Cancer Centre in Melbourne, VIC. She has been working in cancer care for 22 years and the Skin and Melanoma Service at PeterMac for the last 3.5 years. She completed her PhD in 2009 and investigated the perceptions of palliative care held by patients with advanced cancer. During her time in the skin and melanoma service, she developed an interest in the experiences of patients with all stages of melanoma, particularly their quality of life, supportive care needs and interventions required to meet these needs. As a consequence she undertakes research projects with patients with early stage melanoma on routine surveillance; those newly diagnosed with stage 3 or 4 disease and with patients receiving immunotherapy or targeted therapy. She has published in peer-reviewed journals and has presented her research and facilitated a wide range of workshops both nationally and internationally. Dr Milne is driven to promote the benefits of membership with non medical professionals involved with patients with melanoma.
 Doctor Mark Shackleton
MBBS, FRACP, PhD
ANZMTG Executive Member
Doctor Mark Shackleton is a Medical Oncologist and Group Leader of the Melanoma Research Laboratory at the Peter MacCallum Cancer Centre in Melbourne, Victoria. After training in medical oncology in Melbourne and at the Ludwig Institute from Cancer Research, Dr Shackleton undertook his PhD at the Walter and Eliza Hall Institute for Medical Research, and postdoctoral work at the University of Michigan, publishing widely in high impact scientific journals and presenting his research at leading international and national scientific meetings. A winner of the 2006 Victorian Premier’s Award for Medical Research, a 2010 NHMRC Achievement Award, and the 2012 Australian Science Minister’s Prize for Life Scientist of the Year, Dr Shackleton is a current Pfizer Australia Senior Research Fellow, sits on numerous grant and journal review panels and actively participates in melanoma clinical trials. His laboratory at Peter Mac focuses on understanding mechanisms of melanoma initiation and propagation.
Associate Professor Andrew Spillane
MD, MBBS, BMed Sc
ANZMTG Executive Member
Associate Professor Andrew Spillane is an Associate Professor of Surgical Oncology at University of Sydney. He holds appointments at the Discipline of Surgery at the University of Sydney’s Northern Clinical School; the Mater Hospital and Royal North Shore Hospital in North Sydney; and is a Senior Surgeon at Melanoma Institute Australia. He has a research commitment to improving surgical management of melanoma and breast cancer patients and has a particular interest in quality assurance and technical issues of major lymphadenectomy procedures and sentinel node biopsy (SNB) as well as the measuring and reducing morbidity associated with melanoma and breast cancer surgery. He has authored numerous articles in peer-reviewed journals and has presented papers at national and international conferences, and has been actively involved in multi-centred trials. He is currently the Vice-President of Breast Surgeons Society of ANZ and the Deputy Chair of the Breast Section of the RACS and past Chair of the COSA Breast Group. He has a long demonstrated commitment to collaborative translational research. He is the section editor for breast disease for the ANZ Journal of Surgery and a member of the editorial committee for skin oncology for the Journal of Surgical Oncology, and is currently a peer reviewer for >12 international and national journals.
Mr Paul White
ANZMTG Consumer Representative
Mr Paul White is a Fellow of the Institute of Chartered Accountants in Australia and a Certified Internal Auditor. He has 20 years experience in offering assurance advice and business consulting to a range of organisations; from NGO’s, government departments to large public listed companies. Over recent years Paul has built on his years of experience to specialise in risk management. He is now regarded as one the country’s leading developers of risk management frameworks. Paul’s differentiation from his peers is his ability to imbed risk management into the culture of an organisation. Paul is also a melanoma survivor. At the age of 18, Paul was diagnosed with a Level 2 melanoma and despite a number of scares along the way, he has made it to 40 years old and now spends much of his private time investing in relationships within the melanoma community. Paul is currently the Chair of Australian Melanoma Consumer Alliance, the Melbourne Melanoma Consumer Reference Group as well as the ANZMTG Consumer Representative. He believes that well structured research and clinical trials are critical to the elimination of melanoma and that consistent and trusted engagement with patients and families helps build a base for future successful trials.
|